National Health Act 1953 - Determination under paragraph 98C(1)(a) (16/07/1996)

Overview

The National Health Act 1953 was enacted to provide a framework for the regulation and administration of health services in Australia, ensuring that the community has access to affordable and effective healthcare. One of the significant gaps the Act aimed to address was the need for a structured system to regulate the pricing and provision of pharmaceutical benefits. The problem it sought to solve included ensuring that the costs of pharmaceuticals provided under the scheme were sustainable, while also ensuring that these medications remained accessible to those in need. The Act established the Pharmaceutical Benefits Scheme (PBS) to manage the cost of medications, ensuring that they are both affordable and available to the public. The National Health Act 1953 was enacted by the Commonwealth Parliament with the policy objective of providing a comprehensive system for the administration of health services, including the regulation of pharmaceutical benefits. The policy objective of this specific legislative instrument, which was made under paragraph 98C(1)(a) of the Act, is to determine the manner in which the Commonwealth price of a pharmaceutical benefit is ascertained for the purposes of payment to an approved medical practitioner. This determination ensures that the pricing aligns with the provisions of the Act, thereby maintaining the integrity and sustainability of the Pharmaceutical Benefits Scheme.

Scope and Application

The Pharmaceutical Benefits Determination under the National Health Act 1953 pertains to the manner in which the Commonwealth price of a pharmaceutical benefit is ascertained for the purpose of payment to an approved medical practitioner in respect of the supply of a pharmaceutical benefit. This determination applies to all approved medical practitioners involved in the supply of pharmaceutical benefits within Australia, ensuring a consistent approach to the ascertainment of prices in line with the provisions of the National Health Act 1953. The determination affects the entire pharmaceutical industry, including manufacturers, suppliers, and distributors, as it regulates the pricing mechanism integral to the Pharmaceutical Benefits Scheme (PBS). Geographically, the Act applies across the Commonwealth of Australia, ensuring uniform application of the provisions nationwide. The determination excludes any entities or individuals not involved in the supply of pharmaceutical benefits under the PBS. The scope of the Act can be further extended or restricted through subordinate instruments, which may include amendments to the list of approved pharmaceuticals or changes to the pricing methodology.

Key Provisions

The main operative sections of this Determination revolve around the price ascertainment for pharmaceutical benefits under the National Health Act 1953. Section 1 sets the commencement date for this Determination, effective from 1 August 1996. Section 2 revokes a previous Determination made on 18 July 1991, indicating a change in the framework for determining pharmaceutical prices. Section 3 specifies that the manner of ascertaining the Commonwealth price of a pharmaceutical benefit must align with the process outlined in the determination under paragraph 98B(1)(a) of the National Health Act 1953, which is in force at the time the benefit is supplied. This Act imposes specific obligations on parties involved in the supply of pharmaceutical benefits. Firstly, it mandates that the price of a pharmaceutical benefit must be ascertained in accordance with the process specified in the current determination under paragraph 98B(1)(a) of the National Health Act 1953. This requirement ensures consistency and transparency in the pricing mechanism for pharmaceutical benefits. Additionally, the Act necessitates that any changes or updates to the determination must be communicated effectively to ensure all stakeholders are aware of the current pricing procedures. The Act also implies an obligation on the Department of Health and Family Services to monitor and enforce compliance with these pricing stipulations. Failure to comply with the provisions set out in this Determination may result in various consequences. While the Determination itself does not explicitly outline specific offences or penalties, breaches of the National Health Act 1953, which this Determination supplements, could lead to significant civil or criminal penalties. For instance, under the Act, individuals or entities that do not adhere to the specified price ascertainment process may face penalties. These could include fines or other sanctions as stipulated under relevant sections of the Act, reflecting the seriousness of non-compliance in the pharmaceutical benefits framework. The precise penalties would be determined based on the specific provisions of the National Health Act 1953 and any related regulations.